



James H. Godsey, Ph.D.

Dr. Jim Godsey is the Senior Vice President of North America R&D for QIAGEN Gaithersburg Inc., formerly Digene Corporation. He also chairs the QIAGEN Women's Health Portfolio Team and is a member of the QIAGEN America's Management Council. Since joining the organization in October 2006, Dr. Godsey's work has focused on establishing a pipeline of next-generation HPV screening and genotyping assays while driving continuous improvement of the company's R&D capability.

Dr. Godsey served as Vice President, R&D, at Johnson & Johnson's Veridex LLC from June 2005 to October 2006. Under his leadership the company developed the FDA-approved Breast Lymph Node Assay, the first molecular diagnostic alternative to traditional sentinel lymph node dissection, and launched the CellSearch Circulating Tumor Cell System, the first FDA-approved test to determine the prognosis of breast cancer patients suffering from metastatic disease. Additional activities included the identification of novel gene signatures for the prognosis of stage II colon cancer and breast cancer and the development of a PCR-specific methylation assay for prostate cancer.

Prior to joining Veridex, Dr. Godsey was Executive VP, Research, Development, and Clinical Affairs at Gen-Probe Incorporated. Between July 2002 and June 2005, he created Gen-Probe's first cancer diagnostic R&D group, developed and launched over a period of just seven months the nucleic acid test-based blood screening assay for the West Nile Virus, and launched the TIGRIS instrument system for diagnosing sexually transmitted diseases—the first FDA-approved totally automated platform in the molecular diagnostics industry. In 2004, Dr. Godsey adapted the TIGRIS to run the West Nile Virus assay on an individual donor (ID) basis, making it the first high-volume ID test platform successfully utilized in the blood screening industry. His team also started the company's PCA3 (prostate cancer diagnostics) and HPV E6/E7 mRNA (cervical screening) programs, and developed the Panther platform to meet the molecular diagnostics automated testing needs of low- and mid-volume laboratories. Before leaving Gen-Probe, Dr. Godsey submitted a BLA for an HIV/ HCV/Hepatitis B triplex blood screening assay on the TIGRIS, which subsequently resulted in FDA approval and the blood screening industry's first fully automated test platform.

Prior to Gen-Probe, Dr. Godsey served five years as President & COO at ThermoGenesis Corporation, where he helped pioneer robotic archiving systems for the cryopreservation of umbilical cord blood and automated systems for the preparation of fibrin sealant from individual units of allogeneic or autologous plasma. Dr. Godsey's efforts were recently rewarded with the FDA's approval of the CryoSeal System, the first autologous fibrin sealant/thrombin used to stop bleeding after liver resectioning surgery.

Dr. Godsey's 31 years experience in the diagnostics industry includes Dade/Behring's MicroScan division, where he served over an 11 year career as the VP of R&D and, later, Product Line General Manager. Dr. Godsey led the development of MicroScan's totally automated analyzers for rapidly identifying clinically important microorganisms and determining their antibiotic susceptibility patterns.

Contact:

Jim Godsey, Ph.D.
Chair, Women's Health Portfolio Team
Sr. VP, North America R&D
QIAGEN Gaithersburg Inc.
1201 Clopper Road
Gaithersburg, MD 20878
Office (301) 944-7802
Cell (240) 252-8032
jim.godsey@qiagen.com